VIR

Vir Biotechnology, Inc. (VIR) | Rumor.io

Vir Biotechnology

VIR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,292

Bullish sentiment (50-day avg)95%

Price to earnings ratio-3.32

Market capitalization1.8B

Earnings per share-1.77

Dividend yield (TTM)—

Revenue (annual)66.5M

Net income (annual)-438M

Social

What share of all stock conversation is about VIR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Mar 4

H.C. Wainwright raised the price target on Vir Biotechnology (VIR) to $20 from $15 and maintains a Buy rating, citing a "landmark" Astellas collaboration and "compelling" VIR-5500 Phase 1 data.
Vir Biotechnology's President and CEO Marianne De Backer has been appointed, with the company's hepatitis D program progressing ahead of schedule.
Analysts predict Vir Biotechnology's stock price may reach $11 in less than a month, with some expecting a target price of $20 for next week.

Generated by AI

Sentiment

Of the messages about VIR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	95% +0.77	80.43% -4.15
Bearish	—	0% 0	5% -0.77	19.57% +4.15

Bullish· Feb 26

The company's partnership with Astellas is seen as a positive deal that validates the asset and provides a good catalyst for growth.
The recent offering is viewed as a "steal" due to its low price and potential for long-term gains, with some analysts expecting the stock to reach $15 within weeks.
The company's pipeline of products, including its treatment for chronic hepatitis delta, is seen as a significant revenue driver, with some estimates suggesting a market value of $1 billion per year.

Bearish· Feb 26

The company's recent discounted share offering has led to a stock drop.
The offering is seen as a scam, with investors' money being used for bonuses, vacations, and other personal expenses rather than for the company's benefit.
The stock is expected to continue falling, potentially reaching as low as $7.50 or $8.50, as the offering is viewed as a sign of the company's desperation for funds.

Generated by AI

Topics

Of the messages about VIR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	77.78%	64.71%	36.59%	73.06%
Technical Analysis	0%	0%	48.78%	6.92%
Earnings	0%	0%	0%	1.05%
Analysts	22.22%	35.29%	14.63%	10.21%
Controversies	0%	0%	0%	2.14%
Macro	0%	0%	0%	6.62%

Analysts· Aug 27

BofA Securities upgraded Vir Biotechnology (VIR) to Buy from Neutral with a price target of $14, citing the market's underestimation of its asset's potential for treating severe liver disease caused by hepatitis delta virus.
The upgrade is based on improved outlook for VIR's pipeline and execution, with analysts highlighting the potential of its asset and T-cell engager oncology programs.
Vir Biotechnology stock surged 17% in response to the upgrade, with investors attracted to the company's potential in Hepatitis D treatment and early-stage TCE oncology program.

Announcements· Feb 25

Vir Biotechnology's ($VIR) stock jumped after announcing a prostate-cancer partnership with Astellas worth up to $1.71B and positive early data for VIR-5500.
Analysts at Needham, Evercore, and Morgan Stanley raised targets following the partnership, with price targets ranging from $17 to $24 against a current price around $10.
The Astellas deal validates Vir Biotechnology's science and provides capital to execute, with analysts seeing 208% upside if the thesis plays, driven by a $1.7B partnership and a $29.22 analyst target.

Controversies· Mar 25

The FDA has limited the use of Vir Biotechnology's ($VIR) COVID-19 treatment, sotrovimab, in certain US regions due to the high frequency of the Omicron BA.2 sub-variant.
Vir Biotechnology ($VIR) and GlaxoSmithKline ($GSK) are preparing data to support a higher dose of sotrovimab for the Omicron BA.2 sub-variant, which the FDA has deemed unlikely to be effective with the current dose.
The FDA has amended the Emergency Use Authorization Fact Sheet for sotrovimab, citing new live virus data generated by Vir Biotechnology ($VIR) that shows the 500mg dose is unlikely to be effective against the Omicron BA.2 variant.

Technical Analysis· Feb 24

$VIR has broken through resistance levels, with a surge in volume and a classic bull flag chart pattern, indicating a potential target of $12.93.
The stock's price has decisively breached resistance levels, with a 27.59% move confirming the technical breakout structure, and a measured move targeting $13.19.
A bullish breakout has been confirmed, with a massive 25.51M share volume validating the move, and an initial target projecting to $12.80.

Generated by AI

Community

Of the messages about VIR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	95.21%	52.5%
Newcomers	0%	0%	4.79%	47.5%

Regulars· Feb 25

The regulars believe VIR was undervalued when it was in the "$9s" and has long-term potential.
The Ph1 initial data for VIR-5818 in HER2 tumors is expected in the 2H26, and the Ph3 pivotal ECLIPSE-1 trial readout for Hepatitis Delta Virus is expected in 4Q26.
The regulars have a betting record of 196 wins and 50 losses, including a recent win on a bet that VIR would reach 10.49 within 1 day.

Newcomers· Feb 26

Newcomers are warning about buying stocks that gap over 52-week highs, specifically biotech stocks, as they often do secondary offerings, causing prices to drop.
The company's recent announcement of a discounted share offering, with 17,647,058 shares priced at $8.50, has led to a significant drop in stock price.
New investors are questioning the value of Vir Biotechnology stock, with some expressing skepticism about the company's drug development and others pointing to the recent stock drop as a sign of trouble.

Generated by AI

News

Vir Biotechnology Stock: Astellas Deal Highlights The Platform's Value (NASDAQ:VIR)

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. See why VIR stock is a buy.

1d agoSeeking Alpha

Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data

1d agoInvesting.com

Vir Biotechnology stock hits 52-week high at 11.66 USD

28d agoInvesting.com

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

1mo agoYahoo Finance

Vir Biotechnology climbs 9% amid post-earnings uptrend (VIR:NASDAQ)

Vir Biotechnology (VIR) stock jumps after Q2 earnings beat and Astellas deal boosts cash to $1B; preview ECLIPSE catalysts and key levels—read now.

1mo agoSeeking Alpha

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about VIR also mention

#	Name	Attention
1	Janux Therapeutics, Inc.JANX	0%0
2	BioNTech SEBNTX	0%+0
3	CVAC - CureVac N.V.	——
4	Xencor Inc.XNCR	0%new
5	Atea Pharmaceuticals, Inc.AVIR	0%0
6	MORF - Morphic Holding, Inc.	——
7	Immatics N.V.IMTX	0%0
8	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
9	Arcus Biosciences, Inc.RCUS	0%new
10	GSK plc ADRGSK	0%0

Vir Biotechnology, Inc.

Healthcare
Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with significant unmet medical need. Its current portfolio includes programs for chronic hepatitis delta and chronic hepatitis B, alongside multiple solid-tumor candidates built on its PRO-XTEN masking platform. Vir Biotechnology also maintains preclinical research across infectious diseases and oncology, reflecting a pipeline that spans both treatment and prevention. Headquartered in San Francisco, California, Vir Biotechnology plays a role in the broader biotechnology market as a research-driven developer of advanced therapeutic candidates.

Website

Location

1800 Owens Street

San Francisco, CA, 94158

United States

Social

What share of all stock conversation is about VIR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Mar 4

H.C. Wainwright raised the price target on Vir Biotechnology (VIR) to $20 from $15 and maintains a Buy rating, citing a "landmark" Astellas collaboration and "compelling" VIR-5500 Phase 1 data.
Vir Biotechnology's President and CEO Marianne De Backer has been appointed, with the company's hepatitis D program progressing ahead of schedule.
Analysts predict Vir Biotechnology's stock price may reach $11 in less than a month, with some expecting a target price of $20 for next week.

Generated by AI

Sentiment

Of the messages about VIR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	95% +0.77	80.43% -4.15
Bearish	—	0% 0	5% -0.77	19.57% +4.15

Bullish· Feb 26

The company's partnership with Astellas is seen as a positive deal that validates the asset and provides a good catalyst for growth.
The recent offering is viewed as a "steal" due to its low price and potential for long-term gains, with some analysts expecting the stock to reach $15 within weeks.
The company's pipeline of products, including its treatment for chronic hepatitis delta, is seen as a significant revenue driver, with some estimates suggesting a market value of $1 billion per year.

Bearish· Feb 26

The company's recent discounted share offering has led to a stock drop.
The offering is seen as a scam, with investors' money being used for bonuses, vacations, and other personal expenses rather than for the company's benefit.
The stock is expected to continue falling, potentially reaching as low as $7.50 or $8.50, as the offering is viewed as a sign of the company's desperation for funds.

Generated by AI

Topics

Of the messages about VIR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	77.78%	64.71%	36.59%	73.06%
Technical Analysis	0%	0%	48.78%	6.92%
Earnings	0%	0%	0%	1.05%
Analysts	22.22%	35.29%	14.63%	10.21%
Controversies	0%	0%	0%	2.14%
Macro	0%	0%	0%	6.62%

Analysts· Aug 27

BofA Securities upgraded Vir Biotechnology (VIR) to Buy from Neutral with a price target of $14, citing the market's underestimation of its asset's potential for treating severe liver disease caused by hepatitis delta virus.
The upgrade is based on improved outlook for VIR's pipeline and execution, with analysts highlighting the potential of its asset and T-cell engager oncology programs.
Vir Biotechnology stock surged 17% in response to the upgrade, with investors attracted to the company's potential in Hepatitis D treatment and early-stage TCE oncology program.

Announcements· Feb 25

Vir Biotechnology's ($VIR) stock jumped after announcing a prostate-cancer partnership with Astellas worth up to $1.71B and positive early data for VIR-5500.
Analysts at Needham, Evercore, and Morgan Stanley raised targets following the partnership, with price targets ranging from $17 to $24 against a current price around $10.
The Astellas deal validates Vir Biotechnology's science and provides capital to execute, with analysts seeing 208% upside if the thesis plays, driven by a $1.7B partnership and a $29.22 analyst target.

Controversies· Mar 25

The FDA has limited the use of Vir Biotechnology's ($VIR) COVID-19 treatment, sotrovimab, in certain US regions due to the high frequency of the Omicron BA.2 sub-variant.
Vir Biotechnology ($VIR) and GlaxoSmithKline ($GSK) are preparing data to support a higher dose of sotrovimab for the Omicron BA.2 sub-variant, which the FDA has deemed unlikely to be effective with the current dose.
The FDA has amended the Emergency Use Authorization Fact Sheet for sotrovimab, citing new live virus data generated by Vir Biotechnology ($VIR) that shows the 500mg dose is unlikely to be effective against the Omicron BA.2 variant.

Technical Analysis· Feb 24

$VIR has broken through resistance levels, with a surge in volume and a classic bull flag chart pattern, indicating a potential target of $12.93.
The stock's price has decisively breached resistance levels, with a 27.59% move confirming the technical breakout structure, and a measured move targeting $13.19.
A bullish breakout has been confirmed, with a massive 25.51M share volume validating the move, and an initial target projecting to $12.80.

Generated by AI

Community

Of the messages about VIR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	95.21%	52.5%
Newcomers	0%	0%	4.79%	47.5%

Regulars· Feb 25

The regulars believe VIR was undervalued when it was in the "$9s" and has long-term potential.
The Ph1 initial data for VIR-5818 in HER2 tumors is expected in the 2H26, and the Ph3 pivotal ECLIPSE-1 trial readout for Hepatitis Delta Virus is expected in 4Q26.
The regulars have a betting record of 196 wins and 50 losses, including a recent win on a bet that VIR would reach 10.49 within 1 day.

Newcomers· Feb 26

Newcomers are warning about buying stocks that gap over 52-week highs, specifically biotech stocks, as they often do secondary offerings, causing prices to drop.
The company's recent announcement of a discounted share offering, with 17,647,058 shares priced at $8.50, has led to a significant drop in stock price.
New investors are questioning the value of Vir Biotechnology stock, with some expressing skepticism about the company's drug development and others pointing to the recent stock drop as a sign of trouble.

Generated by AI

Vir Biotechnology

Social

Mar 4

Bullish· Feb 26

Bearish· Feb 26

Analysts· Aug 27

Announcements· Feb 25

Controversies· Mar 25

Technical Analysis· Feb 24

Regulars· Feb 25

Newcomers· Feb 26

Vir Biotechnology Stock: Astellas Deal Highlights The Platform's Value (NASDAQ:VIR)

Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data

Vir Biotechnology stock hits 52-week high at 11.66 USD

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology climbs 9% amid post-earnings uptrend (VIR:NASDAQ)

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

Also Discussed

Vir Biotechnology, Inc.

Company Information

Location

Vir Biotechnology Stock: Astellas Deal Highlights The Platform's Value (NASDAQ:VIR)

Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data

Vir Biotechnology stock hits 52-week high at 11.66 USD

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology climbs 9% amid post-earnings uptrend (VIR:NASDAQ)

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Mar 4

Bullish· Feb 26

Bearish· Feb 26

Analysts· Aug 27

Announcements· Feb 25

Controversies· Mar 25

Technical Analysis· Feb 24

Regulars· Feb 25

Newcomers· Feb 26